$RARE

AI 分析

生成于 May 11, 2026

AI Score
48/ 100
Hold$RARE

Ultragenyx Pharmaceutical

$RARENASDAQHealthcareMid-Cap

Ultragenyx develops gene therapies and biologics for rare and ultra-rare diseases.

Market Cap
$4.0B
Revenue (TTM)
$0.5B
+15.0%
Net Income (TTM)
-$0.4B
N/A
EPS (TTM)
-$5.00
P/E Ratio
N/A
Dividend Yield
0.0%
52-Week Range
$38-$65
Beta
0.72
Dimension Scores
Fundamental
40
Technical
48
Sentiment
55
Risk / Reward
42
Momentum
55
FundTechSentRiskMome
Financial Health
Profitability
45weak
Growth
58moderate
Liquidity
50strong
Solvency
42moderate
Efficiency
38moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $RARE

Free · No credit card required

免责声明: AI 生成的分析仅供教育参考,不构成投资建议。请始终咨询合格的理财顾问。

探索更多

用 AI 分析任意股票

获取涵盖基本面、技术面、情绪面、风险评估和投资论点的结构化研究报告——约 60 秒完成。